# James Bochnowski

> James Bochnowski is a Series C investor at Delphi Ventures backing Medical Device and Health Care. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures)
- Location: Menlo Park, United States
- Total investments: 12
- Last investment: Jul 2017
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/jim-bochnowski/12/388/739

James Bochnowski is a Series C investor at Delphi Ventures in Menlo Park focused on Medical Device and Health Care. Jim founded Delphi Ventures in 1988. His focus is on medical devices and biotechnology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 4 | 33% |
| Health Care | 3 | 25% |
| Manufacturing | 2 | 17% |
| Eyewear | 1 | 8% |
| Medical | 1 | 8% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 25% |
| Series D | 3 | 25% |
| Series A | 2 | 17% |
| Series B | 2 | 17% |
| Seed | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Heartbeat | Heartbeat is a platform for millennial women to join, provide feedback to, and promote brands via their personal networks. Heartbeat has matched the millennial generation’s natural passion for self-promotion with a turn-key solution for brands to engage Ambassadors at scale.Coordinating large-scale Ambassador campaigns used to take 6 months. | $450K | Seed | Jul 17, 2017 |  |
| Sequent Medical | Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new optionfor the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany. | $20M | Series D | Apr 08, 2014 |  |
| Sequent Medical | Founded in 2007, Sequent Medical, Inc. is a privately-held venture backed medical device company dedicated to the development of innovative catheter-based neurovascular technologies. The company has invented and developed the proprietary Microbraid™ technology to create the WEB™ Aneurysm Embolization System, a compelling and versatile new optionfor the treatment of both ruptured and unruptured aneurysms. The WEB has received the CE mark and to date has been used to treat a wide variety of nearly 600 aneurysms in Europe, Latin America and New Zealand. The WEB is not available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California and has European operations based in Bonn, Germany. | $26M | Series C | Mar 06, 2012 |  |
| PixelOptics | PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses. | $45M | Series D | Apr 07, 2011 |  |
| ELENZA | ELENZA, Inc. is developing the world's first electronic "AutoFocal" Intraocular Lens to compete in the multi-billion dollar IOL market. Elenza's highly proprietary next generation Accommodating IOL is designed to give patients a complete visual range, providing effective near, intermediate and distance vision. Theseelectro-active IOLs use a proprietary combination of liquid-crystal chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over the full range of vision. The technology includes an electro-active switchable element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in-focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life. | $24M | Series B | Feb 08, 2011 |  |
| PhotoThera | PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information.Specialtieslaser, medical device, eschemic, stroke,infrared | $50M | Series D | May 22, 2009 |  |
| ELENZA | ELENZA, Inc. is developing the world's first electronic "AutoFocal" Intraocular Lens to compete in the multi-billion dollar IOL market. Elenza's highly proprietary next generation Accommodating IOL is designed to give patients a complete visual range, providing effective near, intermediate and distance vision. Theseelectro-active IOLs use a proprietary combination of liquid-crystal chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over the full range of vision. The technology includes an electro-active switchable element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in-focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life. | $6M | Series B | Dec 18, 2008 |  |
| PixelOptics | PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses. | $30M | Series C | Oct 23, 2008 |  |
| ELENZA | ELENZA, Inc. is developing the world's first electronic "AutoFocal" Intraocular Lens to compete in the multi-billion dollar IOL market. Elenza's highly proprietary next generation Accommodating IOL is designed to give patients a complete visual range, providing effective near, intermediate and distance vision. Theseelectro-active IOLs use a proprietary combination of liquid-crystal chemistry, electricity, and integrated-circuitry to create smart optics, which will provide patients with the ability to see more naturally and clearly over the full range of vision. The technology includes an electro-active switchable element that automatically adjusts focusing power electronically, in milliseconds, to maintain constant in-focus vision for various working needs and/or light environments. The lens is controlled by a micro-sized power-cell with an expected 50+ year rechargeable cycle life. | $497K | Series A | Jul 01, 2008 |  |
| PixelOptics | PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses. | $23.8M | Series B | Jan 09, 2008 |  |

10 of 12 investments shown.

## Co-investors
- [DeNovo Ventures](https://shizune.co/investors/profile/denovo-ventures) — VC Fund, 2 deals together
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 2 deals together
- [The Vertical Group](https://shizune.co/investors/profile/the-vertical-group) — VC Fund, 2 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 1 deal together
- [Hamilton BioVentures](https://shizune.co/investors/profile/hamilton-bioventures) — VC Fund, 1 deal together
- [PLG Ventures](https://shizune.co/investors/profile/plg-ventures) — VC Fund, 1 deal together

## About Delphi Ventures

VC Fund · San Mateo, United States

Delphi Ventures is a venture capital firm that has focused on investing in biotechnology and medical devices for over two decades. With more than $1.1 billion in committed capital, Delphi Ventures has funded over 170 companies. More than 110 of our portfolio companies have either completed an initial public offering or have been acquired by aleading healthcare corporation.

5 contacts available at Delphi Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Deepika R Pakianathan | General Partner | https://shizune.co/investors/profile/deepa-r-pakianathan |
| Doug Roeder | General Partner | https://shizune.co/investors/profile/doug-roeder |
| James Bochnowski | Founder & Managing Member | https://shizune.co/investors/profile/james-j-bochnowski |
| Matthew T. Potter | CFO\| Partner | https://shizune.co/investors/profile/matthew-t-potter |
| David L. Douglass | General Partner | https://shizune.co/investors/profile/david-l-douglass |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does James Bochnowski invest in?

James Bochnowski invests primarily in Medical Device, Health Care and Manufacturing startups, most often at Series C and Series D stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did James Bochnowski last invest?

The most recent investment recorded for James Bochnowski closed in Jul 2017. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co